NextCure Bags $40 Million from Eli Lilly

Lilly hopes to leverage NextCure’s FIND-IO technology for cancer immunotherapy development.

Eli Lilly is committed to expanding its position in the cancer immunotherapy space. Earlier in 2018 the company acquired cytokine drug developer Armo Biosciences for $1.6 billion and AurKa Pharma, which develops drugs that target cancer growth enzymes referred to as Aurora kinases.

The latest move by Eli Lilly is a collaboration with NextCure, a biotech company that identifies molecular targets that when correctly modulated can drive immune responses to tumors. 

As part of this latest collaboration, Lilly will pay NextCure $25 million upfront and invest $15 million in NextCure equity. Both companies have the option to license any antibodies identified during the collaboration using NextCure’s FIND-IO technology, which identifies molecular interactions that affect immune responses in the tumor microenvironment. NextCure will receive additional milestone payments and royalties on sales if Lilly further develops and commercializes any drugs as a result of the partnership.

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.